Apixaban.
Article Details
- CitationCopy to clipboard
Cada DJ, Levien TL, Baker DE
Apixaban.
Hosp Pharm. 2013 Jun;48(6):494-509. doi: 10.1310/hpj4806-494.
- PubMed ID
- 24421512 [ View in PubMed]
- Abstract
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The June 2013 monograph topics are dimethyl fumarate (BG-12) delayed-release capsules, canagliflozin, ospemifene, aripiprazole extended-release injectable, and dabrafenib. The DUE/MUE is on dimethyl fumarate.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Apixaban Cytochrome P450 1A2 Protein Humans UnknownSubstrateDetails Apixaban Cytochrome P450 2C19 Protein Humans UnknownSubstrateDetails